Suryanarayana Rayapureddi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suryanarayana Rayapureddi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Daniel R. Saban
Duke University School of Medicine, Departments of Ophthalmology and Immunology, Durham, North Carolina, USA
1 shared publicationDavid J. Abraham
Centre for Rheumatology and Connective Tissue Diseases, University College London, Royal Free Campus, London, United Kingdom
1 shared publicationJill T. Norman
Centre for Nephrology, University College London, Royal Free Campus, London, United Kingdom
1 shared publication- John Kenneth George Dart
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
1 shared publication Julie T. Daniels
Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, London, United Kingdom
1 shared publication- Markella Ponticos
Royal Free and University College Medical School, London, UK
1 shared publication
Latest Publications
- Open Access
- 4 August 2016
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 1 (12) , e87001
Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring
Mucous membrane pemphigoid (MMP) is a systemic mucosal scarring disease, commonly causing blindness, for which there is no antifibrotic therapy. Aldehyde dehydrogenase family 1 (ALDH1) is upregulated in both ocular MMP (OMMP) conjunctiva and cultured fibroblasts. Application of the ALDH metabolite, retinoic acid (RA), to normal human conjunctival fibroblasts in vitro induced a diseased phenotype. Conversely, application of ALDH inhibitors, including disulfiram, to OMMP fibroblasts in vitro restored their functionality to that of normal controls. ALDH1 is also upregulated in the mucosa of the mouse model of scarring allergic eye disease (AED), used here as a surrogate for OMMP, in which topical application of disulfiram decreased fibrosis in vivo. These data suggest that progressive scarring in OMMP results from ALDH/RA fibroblast autoregulation, that the ALDH1 subfamily has a central role in immune-mediated ocular mucosal scarring, and that ALDH inhibition with disulfiram is a potential and readily translatable antifibrotic therapy.
- 4 August 2016
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 1 (12) , e87001
Open AccessAldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring
Mucous membrane pemphigoid (MMP) is a systemic mucosal scarring disease, commonly causing blindness, for which there is no antifibrotic therapy. Aldehyde dehydrogenase family 1 (ALDH1) is upregulated in both ocular MMP (OMMP) conjunctiva and cultured fibroblasts. Application of the ALDH metabolite, retinoic acid (RA), to normal human conjunctival fibroblasts in vitro induced a diseased phenotype. Conversely, application of ALDH inhibitors, including disulfiram, to OMMP fibroblasts in vitro restored their functionality to that of normal controls. ALDH1 is also upregulated in the mucosa of the mouse model of scarring allergic eye disease (AED), used here as a surrogate for OMMP, in which topical application of disulfiram decreased fibrosis in vivo. These data suggest that progressive scarring in OMMP results from ALDH/RA fibroblast autoregulation, that the ALDH1 subfamily has a central role in immune-mediated ocular mucosal scarring, and that ALDH inhibition with disulfiram is a potential and readily translatable antifibrotic therapy.